Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01122849 · ClinicalTrials.gov registry record · Phase 2
Exploratory Subjective Sleep Study of a Prototype Nasal Dilator
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT01122849: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT01122849 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 61 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01122849, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this exploratory study is to evaluate the subjective measures of congestion and sleep quality in subjects who suffer from chronic nasal congestion and report trouble with their sleep.
Primary Outcome
The PIRS questionnaire had 3 sections (Section A \[Q1 to Q12\], Section B \[Q13 to 16\] and Section C \[Q17 to Q20\]). The following questions were asked from Section A : 1. One or more awakenings after getting to sleep and 3 Sleep that does not fully refresh you, and Section C: 17 Your sleep quality compared to most people and 18 Your satisfaction with your sleep. Section A question were scored as follows: 0= Not at all bothered, 1= slightly bothered, 2=moderately bothered, and 3= severely both
Interventions
- DEVICE Marketed Nasal Strip
- DEVICE Prototype Nasal Dilator
- DEVICE Placebo Nasal Strip
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2009-10-01 |
| Est. Completion | 2010-02-01 |
| Phase | Phase 2 |
What the finished NCT01122849 record still lists
NCT01122849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 3 interventions - of which Marketed Nasal Strip is the first listed.
NCT01122849 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01122849 about?
NCT01122849 is a clinical study titled "Exploratory Subjective Sleep Study of a Prototype Nasal Dilator". The purpose of this exploratory study is to evaluate the subjective measures of congestion and sleep quality in subjects who suffer from chronic nasal congestion and report trouble with their sleep.
What is the current status of trial NCT01122849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2009-10-01. Estimated completion is 2010-02-01.
What interventions are being tested in trial NCT01122849?
The interventions under investigation include: Marketed Nasal Strip (DEVICE), Prototype Nasal Dilator (DEVICE), Placebo Nasal Strip (DEVICE).
Who is sponsoring clinical trial NCT01122849?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01122849's enrollment target sits among peer trials
61 1026th of 2000 higher than 974 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI